Extended Data Fig. 4: Change in serum AST and GGT levels after 12 weeks of treatment with licogliflozin. | Nature Medicine

Extended Data Fig. 4: Change in serum AST and GGT levels after 12 weeks of treatment with licogliflozin.

From: Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Extended Data Fig. 4: Change in serum AST and GGT levels after 12 weeks of treatment with licogliflozin.

a, AST; b, GGT. Data presented as geometric mean ratio to baseline. Baseline is defined as the mean of measurements taken at the screening and baseline visits. A repeated-measures ANCOVA was performed for the log-transformed ratio to baseline. P values based on two-sided ANCOVA test: *P < 0.05, **P < 0.01, and ***P < 0.001. Error bars represent s.e. n for placebo, licogliflozin 30 mg, and licogliflozin 150 mg for AST: 21, 42, 38 (day 7); 21, 43, 36 (day 14); 21, 41, 33 (day 28); 20, 40, 33 (day 56); 20, 40, 34 (day 84); 19, 39, 34 (EOS); GGT: 21, 42, 38 (day 7); 21, 43, 36 (day 14); 21, 42, 34 (day 28); 20, 42, 34 (day 56); 20, 40, 34 (day 84); 19, 39, 34 (EOS). Dotted gray line represents end-of-treatment time point.

Back to article page